Hong Kong · Delayed Price · Currency is HKD CANbridge Pharmaceuticals Company Description
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis.
It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease.
In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy.
It has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli.
CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
| Country | Cayman Islands |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Qun Xue |
Contact Details
Address: Suzhou Industrial Park, Building 21 Suzhou China | |
| Phone | 86 10 6478 0016 |
| Website | canbridgepharma.com |
Stock Details
| Ticker Symbol | 1228 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG8587E1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Qun Xue M.B.A., Ph.D. | Founder, Chairman of the Board, Chief Executive Officer and Member of Strategic Advisory Board |
| Lillian Zhang | Senior Director and Head of Finance Operations and Controller |
| Joe Shen | Chief Operating Officer |
| Qian Ma | Vice President and General Counsel |
| Chris Chen | Vice President of Human Resources |
| Dr. Gerald F. Cox M.D., Ph.D. | Chief Development Strategist and Interim Chief Medical Officer |
| Rebecca Zhang | Chief Regulatory Advisor |
| Dr. Jeff Kou Ph.D. | Head of Clinical Operations and Senior Director of Research & Development Strategy and Portfolio Management |
| Dr. Jason West | Head of Global Gene Therapy Research |
| Will Wang | Executive Director of Production |